Dr Emma Longland

Patent Director

Emma entered the patent profession in 2007, working in private practice and joining HGF Limited as a Senior Patent Attorney in July 2016. She is experienced in all aspects of patent practice, and works in our Life Sciences Group with a particular focus on inventions in the CRISPR field.

Emma has always had a wide-ranging practice, working for clients in many different fields, although with an emphasis on the medical and biotechnology fields. This has included cases concerning, for example, nucleic acid extraction, amplification, and sequencing, vaccines, humanised antibodies, anti-cancer pharmaceuticals, treatments for autism-spectrum disorders, and medical devices. In recent years, Emma has been providing specialised advice to clients in the gene editing space, including those exploiting CRISPR systems. Emma particularly provides expertise for the drafting and prosecution of patent applications, and the defending and attacking of patents during EPO oppositions and appeals proceedings.

Emma has an MA in Natural Sciences, an MSci, specialising in Biochemistry, and a PhD, all from the University of Cambridge.  Her PhD research involved investigating the transcriptome changes that occur during the development of HPV-induced cancers of the uterine cervix.

In 2012, Emma achieved the highest score among those, throughout Europe, sitting the European Qualifying Examinations Amendment (Chemistry) paper.